Search | Clinical Trials Finder

Conditions: Cancer
Interventions: hand-held POC creatinine analyzer-blood test; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 12
States / cities: Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more

Conditions: Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions: Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High; Drug
Lead sponsor: ARKAY Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Albany, New York

Conditions: Epilepsy
Interventions: Ganaxolone; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 6 more

Conditions: COVID-19 Virus Infection, COVID-19, Coronavirus Disease-19, COVID-19 Pandemic, SARS-CoV-2 Infection
Interventions: iStatis COVID-19 Ag Rapid Test, "COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America ("Labcorp"); Diagnostic Test
Lead sponsor: bioLytical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Elkridge, Maryland

Conditions: Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
Interventions: SPI-62, Placebo; Drug
Lead sponsor: Sparrow Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more

Conditions: Uncontrolled Hypertension
Interventions: Baxdrostat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Tempe, Arizona • Montclair, California + 6 more

Conditions: Idiopathic Focal Segmental Glomerulosclerosis
Interventions: Acthar Gel; Drug
Lead sponsor: Mallinckrodt ARD LLC; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 21
States / cities: Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Acthar, Placebo, Steroid Drug; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: ACTH, Placebo; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more

Conditions: Type 1 Diabetes
Interventions: Dexcom G7 rtCGM, Capillary Blood glucose Testing (POC); Device · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hyperglycemia, Hypoglycemia, Critical Illness, Diabetes Mellitus
Interventions: Continuous glucose monitoring, Point of care glucose monitoring; Device
Lead sponsor: Malcom Randall VA Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: GW876008, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Sherwood, Arkansas • Concord, California • Los Angeles, California + 14 more

Conditions: Sarcoid Uveitis
Interventions: H.P. Acthar gel; Drug
Lead sponsor: John Huang, MD; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Hamden, Connecticut

Conditions: Uveitis
Interventions: ACTH gel; Drug
Lead sponsor: Quan Dong Nguyen; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Waltham, Massachusetts + 3 more

Conditions: Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Interventions: Pathogen Reduced Cryoprecipitated Fibrinogen Complex; Biological
Lead sponsor: Cerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Advanced Dry Macular Degeneration
Interventions: Alpha MSH assay; Device
Lead sponsor: Duke University; Other
Eligibility: 60 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Maternal Syphilis During Pregnancy - Baby Not Yet Delivered, Congenital Syphilis
Interventions: Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ); Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: HIV Infections, Syphilis
Interventions: Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis, NOS
Interventions: BMS-582949, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Palm Desert, California • Santa Monica, California • Las Vegas, Nevada + 5 more

Conditions: Bronchiectasis
Interventions: Itepekimab (SAR440340), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions: BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota

Conditions: COPD
Interventions: Portable Oxygen Concentrator (POC); Device
Lead sponsor: ResMed; Industry
Eligibility: 40 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Denver, Colorado • Chicago, Illinois • Indianapolis, Indiana + 8 more

Search by objective public record fields.

Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies

Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

ACTH for Fatigue in Multiple Sclerosis Patients

A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes

Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

(ACTH) for the Treatment of Sarcoid Uveitis

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

PARA-HEART Pilot Implementation

Alpha MSH in Ocular Disease

Point-Of-Care Testing for Congenital Syphilis in Mothers and Newborns

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

PoC in Rheumatoid Arthritis With Methotrexate

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)